access intranet after hours circle-arrow apply blog caret circle arrow close closer look community outreach community outreach contact contact us down arrow facebook lock solid find a provider find a clinical trial find a provider find a researcher find faculty find-a-service how to apply join leadership left arrow locations logo make a gift map location maximize minimize my chart my chart notification hp notification lp next chevron right nxt prev pay your bill play previous quality and safety refer a patient request a speaker request appointment request an appointment residents corner rss search search jobs Asset 65 submit a story idea symptom checker Arrow Circle Up twitter youtube Dino Logo External Link University Logo Color University Logo Solid Health Logo Solid Arrow Right Circle Book Calendar Date Calendar Search Date Diploma Certificate Dollar Circle Donate Envelope Graduation Cap Map Pin Map Search Phone Pills Podcast

IRB Submission Process

Research Integrity

New Application - Determine the Type of Application to Prepare

The Office for Human Research Protections (OHRP) provides Human Subject Regulations Decision Charts to guide IRBs, investigators, and others to decide if an activity is research involving human subjects that must be reviewed by an IRB. The charts address decisions on the following:

  • Whether an activity is research that must be reviewed by an IRB

  • Whether the review may be performed by expedited procedures, and

  • Whether informed consent or its documentation may be waived.

The MUSC QI Self-Certification tool allows study teams to make the decision about whether their project constitutes the definition of research under the Common Rule (45 CFR 46) independent of the IRB. The tool is designed to help determine whether the project constitutes research or whether it is quality improvement or program evaluation, such that IRB review isn’t required. If, based on the questions and responses in the completed tool, the project does not constitute research, the tool provides a certification. This certification can be printed off and used as documentation that the project does not constitute research and further IRB review is not required. This certification takes the place of a formal submission in eIRB and subsequent certification notice from the MUSC IRBs. If completion of the tool indicates the project may require IRB review, any indication of certification from the tool is considered invalid.

eIRB 21CFR Part 11 Compliance Info (PDF)

Approved Protocols

Select the link appropriate to the type of activity to be communicated to the IRB.

ERMA 

ERMA has been in place since 2004. Any protocol with starting with HR (ex. HR11111) resides in ERMA.

All Continuing Reviews, Amendments, Protocol Deviation, and Adverse Event reports to be submitted on IRB-approved protocols with an HR number, should be entered in ERMA.

eIRB

Protocols have a PRO prefix (ex. PRO00001111).

All Continuing Reviews, Amendments, and reportable events to be submitted on IRB-approved protocols with PRO number, should be entered in eIRB.

Principal Investigator's Statement of Assurance

The Statement of Assurance certifies that the PI will carry out the proposed research in compliance with IRB policy.

In ERMA, this signature page is a separate document. If there is a change in PI of an approved study, then the new PI must submit a signed Statement of Assurance. The signed Statement of Assurance can be delivered or faxed to the IRB to complete the application process. By signing this statement, the PI's signature will no longer be required on IRB forms with two exceptions:

In eIRB, the PI completes this online in submitting the protocol for review.

Applications That the IRB Determines Are Not Ready for Review

When the IRB receives an application that is prepared in such a way that the proposed research procedures are unclear or large components of the application are missing, reviewers will be unable to provide meaningful comments and guidance. In such cases, the application will be withdrawn in eIRB, and recommendations for additional resources and guidance will be provided to the PI. Below are some examples of scenarios in which the IRB may determine that an application is not ready for review:

  • Missing or inadequately prepared essential documents, including:
    • Protocol
    • Consent form(s)
    • Questionnaire(s) or focus group materials when the main component of the study is the administration of that material
    • Documentation needed to determine the engagement level of any off-campus study sites
    • Drug or device documentation
  • Inconsistent or unclear description of procedures such that the reviewers are uncertain of what is being proposed
  • Project described does not seem to constitute research with human subjects as written
  • Recurrent errors throughout the application and attachments to the extent that a detailed review and revision of the entire application is needed Information presented in the SmartForm is not in agreement with the information provided in the protocol, ICF and other supporting documents

When an application is withdrawn in this manner, the recommendation from the IRB is to:

  • Seek help from the free on-campus research support services at the SUCCESS center
  • Talk with Principal Investigator’s Mentor to receive guidance on how to provide a complete application.
  • Set up a meeting with the IRB Administrator and Chair

 *Please refer to the SUCCESS center website to request regulatory services.

Guidelines for Research Involving Cancer Patients, the Hollings Cancer Center (HCC) or Any Research Addressing Cancer

In accordance with the operational guidelines involved with the National Cancer Institute (NCI) designation of the Hollings Cancer Center (HCC) and the HCC Protocol Review and Monitoring System, all MUSC patient-oriented human subjects research involving cancer patients or cancer-related aims (including cancer-related epidemiological or diagnostic trials involving healthy patients) must be reviewed by the HCC Protocol Review Committee (PRC).

In eIRB, protocols indicating use of either Hollings Cancer Center or is Cancer-related research will automatically be routed to the PRC. Any prospective cancer-related institutionally sponsored trial must be PRC reviewed and approved PRIOR to IRB review. This includes trials that are led by MUSC and have outside funding or support. All other prospective cancer-related studies may have PRC review and IRB review occur simultaneously. However, the HCC PRC approval must be obtained and submitted in eIRB before an IRB approval is released.

For more information about studies subject to PRC review and the PRC review process, please contact the PRC at 843-792-9247 or 843-792-1753. PRC information is also located on the MUSC Intranet. A valid NetID is required.

IRB Fees

Effective July 1, 2017, the IRB charges the following fees:

Initial Protocol Review

No Sponsor - MUSC Faculty: $100
(There are no fees for trainees, students, or VA submissions.)

Industry Sponsored Studies

Initial Protocol Review: $2,500
Continuing Review (Annually): $750

Amendments

Full Board & Expedited (does NOT apply to personnel* or administrative change): $500
*with the exception of change in PI

Reliance Requests

You may request the MUSC IRB rely on an external IRB for review and approval of your research, or the MUSC IRB provide approval for non-affiliated investigators or sites.

Please see Reliance Requests for further information on Reliance arrangements. To request reliance on Western IRB, visit the Western IRB Submission Process.